DECN Decision Diagnostics Corporation (CE)

DECN RECEIVES "NO COMMENT" LETTER FROM SEC, PROVIDING THE COMPANY THE ABILITY, UPON FORMAL                          QUALIFICATION, TO RAISE UP TO $7.5MM IN FINANCING UNDER REGULATION A

Los Angeles, CA -- September 6, 2018 -- InvestorsHub NewsWire -- Decision Diagnostics Corp. (OTC PINK: DECN) (the “Company”) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, the clinical trial in process GenChoice! ("Ladybug") test strip, the market ready PetSure! test strip for the diabetic testing of dogs and cats, and the GenPrecis! ("Dragonfly") diabetes testing system, ready for clinical trials.

Decision Diagnostics is pleased to announce that the Securities and Exchange Commission (“SEC”) Staff completed its initial review of our proposed offering under Regulation A, for up to $7.5 million, by sending a “no comment” letter. On July 31, 2018 DECN filed a preliminary Offering Statement on Form 1-A including a preliminary Offering Circular pursuant to  Regulation A under the Securities Act of 1933 (the “Offering Statement”). During the interim period, the Offering Statement was subject to review and potential comment letters from the SEC Staff. DECN is pleased to announce that the SEC Staff has returned a response, in less than four weeks of the date of filing, with no comments. As a result, the offering statement can potentially be qualified by the Company with the SEC as soon as several actions are taken by the company, including qualification for Blue Sky status in at least one state, and once the Company’s placement agent (if any) clears its compensation arrangements with FINRA. We have begun these actions. DECN will make a further announcement upon the qualification of the Offering Statement.

CEO Keith Berman commented, “This latest evolution in our capital structure positions us to, at our discretion, raise additional working capital from traditional capital markets with our Reg A+ Offering Statement. We believe the offering, if successful, will give us the ability to expand into the many product divisions that we have been communicating recently to all of DECN’s stakeholders. This accomplishment is no small achievement.”

ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is a manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. Recently the company added a glucose testing product, to be used by pet owners, to its product mix.


FORWARD-LOOKING STATEMENTS:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of September 5, 2018, regarding the Company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

LEGAL DISCLAIMER:
An offering statement pursuant to Regulation A related to certain of our securities has been filed with the Securities and Exchange Commission. Information contained in the preliminary offering circular is subject to completion or amendment. No money or consideration is being solicited by the information in this press release or any other communication and, if sent, money will not be accepted and will be promptly returned. No offer by a potential investor to buy our securities can be accepted and, if made, any such offer can be withdrawn before qualification of this offering by the Commission. A potential investor’s indication of interest does not create a commitment to purchase the securities we are offering. Any such indication of interest may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance is given and all other requirements to accept an investment from a potential investor are met after the offering qualification date.

Securities may not be sold nor may offers to buy be accepted before the offering statement filed with the Commission is qualified. This press release and the preliminary offering circular does not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sales of securities in any state in which such offer, solicitation or sale would be unlawful before registration or qualification under the laws of such state.

The preliminary offering circular can be obtained at the following link:

https://www.sec.gov/archives/edgar/data/1144225/000107878218000766/f1aoffering_1a.htm

CONTACT INFORMATION:
Decision Diagnostics Corp.    
Keith Berman (805) 446-2973         
Joanne Broeders (305) 340-1000     

info@decisiondiagnostics.com
www.genultimate.com
www.petsureteststrips.com
www.pharmatechdirect.com
 

Grafico Azioni Decision Diagnostics (CE) (USOTC:DECN)
Storico
Da Ott 2024 a Nov 2024

Grafico Azioni Decision Diagnostics (CE) (USOTC:DECN)
Storico
Da Nov 2023 a Nov 2024